Biomind Labs Launches C$2.52 Million Private Placement to Fund CNS Drug Pipeline

Biomind Labs Inc ( (TSE:BMND) ) has provided an announcement.

Biomind Labs Inc. announced plans for a non-brokered private placement of up to 28 million units at C$0.09 per unit, for potential gross proceeds of up to C$2.52 million, with each unit consisting of one common share and a warrant exercisable at C$0.12 for 24 months. The financing, expected to close in early February subject to regulatory approvals and standard conditions, is intended to fund the advancement of Biomind’s clinical development programs, regulatory preparations and general working capital, underscoring the company’s ongoing capital-raising efforts to support its pipeline in CNS-focused biopharmaceutical innovation.

More about Biomind Labs Inc

Biomind Labs Inc. is a clinical-stage biopharmaceutical company that develops novel pharmaceutical drugs and proprietary nanotechnology-based delivery systems targeting psychiatric and neurological conditions affecting the central nervous system. Leveraging translational neuroscience and formulation science, the company focuses on optimizing the pharmacological profile of endogenous and naturally derived molecules to address unmet needs in CNS therapeutics, emphasizing rigorous clinical validation and patient-centric innovation.

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$1.15M

For an in-depth examination of BMND stock, go to TipRanks’ Overview page.